Tamoxifen Does Not Affect Sexual Functioning or Mood Swings

Publication
Article
OncologyONCOLOGY Vol 15 No 6
Volume 15
Issue 6

Contrary to speculation, long-term use of tamoxifen (Nolvadex) does not affect mood or sexual functioning, according to British researchers who studied the use of this antiestrogenic drug in women who are at high risk of developing breast cancer

Contrary to speculation, long-term use of tamoxifen(Nolvadex) does not affect mood or sexual functioning, according to British researchers who studied the use of thisantiestrogenic drug in women who are at high risk of developing breast cancer.

Menopausal Symptoms

Published in a recent issue of the Journal of Clinical Oncology(19:1885-1892, 2001), the study was based on information from two ongoingBritish double-blind, randomized trials of tamoxifen vs placebo over 5 years in488 women. As expected, the researchers found that tamoxifen users hadsignificantly more hot flashes (42% vs 29%), night sweats (43% vs 29%), and coldsweats (10% vs 3%), compared to the control group. Tamoxifen blocks the brain’suse of estrogen, thus producing menopause-like symptoms.

But, beyond these menopausal symptoms, there were no significantoverall quality of life differences between the groups, and tamoxifen had noeffect on overall sexual activity: 80% of tamoxifen users were sexually active,compared to 75% in the placebo group. Also, more placebo users than tamoxifenrecipients reported mood swings over the 5-year study (26% vs 22%), but theresearchers concluded that those mood changes were largely unrelated to theclinical trial.

Encouraging Results

"This is good news for women at high risk of breast cancerwho are considering using tamoxifen," said Lesley Fallowfield, PhD, of theUniversity of Sussex. "Much publicity has been generated by various groupswho believe that the antiestrogenic effects of tamoxifen can be damaging to awoman’s health. We certainly should never underestimate the effect ofmenopausal symptoms on a patient’s quality of life, but our results areencouraging."

Tamoxifen is a complex drug that can have estrogenic effects oncertain parts of the body such as the uterus (similar to hormone replacementtherapy) as well as antiestrogenic effects on the heart and brain. "Thisexplains why its overall effect on things like sexual activity may be morebalanced than once thought," said Dr. Fallowfield.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.